Abaloparatide | CAS 247062-33-5 | PTHrP Analogue / PTH1R Agonist (Research Use Only) | Knowlux

Product Description

Abaloparatide, CAS 247062-33-5, is a synthetic 34-amino-acid peptide analogue of human parathyroid hormone-related protein (PTHrP) supplied by Knowlux for laboratory research use. It is also known by the brand name Tymlos. The molecular formula is C174H300N56O49 and the molecular weight is 3960.59 g/mol. Each lot is released with a lot-specific COA, MSDS and full analytical traceability.

Sequence and structural clarification: The peptide sequence is Ala-Val-Ser-Glu-His-Gln-Leu-Leu-His-Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-Leu-Arg-Arg-Arg-Glu-Leu-Leu-Glu-Lys-Leu-Leu-Aib-Lys-Leu-His-Thr-Ala-NH2, where Aib denotes alpha-aminoisobutyric acid at position 29. The molecule shares approximately 41% homology with PTH(1-34) (teriparatide) but incorporates multiple substitutions in the 22-34 region designed to enhance stability and alter receptor conformation selectivity. Abaloparatide is approved by the FDA (Tymlos, 2017) for postmenopausal osteoporosis and for increasing bone density in men with osteoporosis; that approval is specific to the finished pharmaceutical product and does not extend to this research-grade supply.

Product Parameters

Product Details

1. Overview

Abaloparatide is a synthetic peptide analogue of human PTHrP(1-34), developed as a second-generation osteoanabolic agent for osteoporosis. Unlike teriparatide, which is derived from PTH(1-34), abaloparatide was engineered from PTHrP with specific substitutions (including Aib at position 29) intended to stabilize the peptide and modulate its interaction with the PTH1R receptor. In research settings, abaloparatide is studied as a tool compound for dissecting PTH1R conformation selectivity, biased agonism, and the differential downstream signalling that distinguishes bone formation from bone resorption. Knowlux supplies abaloparatide as a research-grade peptide for laboratory and analytical use; this supply is not intended for human administration and does not constitute a finished drug product.

2. Mechanism of Action (Research Context)

Published research describes abaloparatide as a selective PTH1R agonist with a distinct signalling profile compared to PTH(1-34). The PTH1R exists in two conformational states: RG (GTPgammaS-sensitive) and R0 (GTPgammaS-insensitive). Abaloparatide binds preferentially to the RG conformation, while teriparatide has a four-fold higher affinity for the R0 state. This conformational selectivity results in transient cAMP signalling for abaloparatide, whereas teriparatide produces prolonged cAMP elevation. The downstream consequence is that abaloparatide stimulates bone formation with relatively less induction of osteoclastogenic cytokines (RANKL and M-CSF) and a lower RANKL/OPG ratio, thereby preserving the anabolic window that is lost with teriparatide over time. In cellular assays, abaloparatide showed a markedly lower EC50 for cAMP formation (2.3-fold) and beta-arrestin recruitment (1.6-fold) than teriparatide, consistent with its enhanced potency at the RG conformation. These descriptions are derived from published research and are provided for scientific reference only. Knowlux makes no claims regarding the efficacy, safety, or suitability of this product for any human application. Promotion of abaloparatide for osteoporosis treatment, fracture prevention, or any clinical indication is not supported by Knowlux and is inconsistent with research-use-only supply.

3. Quality Control

Full COA, MSDS, and lot-specific chromatograms are issued with each shipment. Custom specifications and third-party inspection can be arranged.

4. Applications

• Reference standard for PTHrP analogue analytical method development

• In vitro PTH1R conformation selectivity and biased agonism studies

• cAMP signalling and beta-arrestin recruitment assay development

• Bone formation and osteoblast/osteoclast signalling research models

• Comparative studies of PTH(1-34) vs PTHrP analogues

• LC-MS and immunoassay calibrators

5. Packaging, Storage & Shipping

Lyophilized powder: amber glass vial under nitrogen headspace, sealed with butyl stopper and aluminium crimp. Secondary packing: tamper-evident, light-protected carton with desiccant. Cold-chain shipping with validated gel packs and temperature logger; dry ice for -20 C shipments. COA, MSDS, packing list and certificate of origin issued with each shipment.

6. Documentation Support

Per lot: COA, MSDS, certificate of origin, residual solvent statement, counter-ion specification. Regulatory packages (specification summaries, audit support) available on a project basis.

About Knowlux

Knowlux Biotechnology is a GMP-oriented manufacturer and supplier of peptides, APIs and fine-chemical research compounds, operating from Hubei, China. We serve research groups, CDMOs and distributors in more than 40 countries, and support contract synthesis, custom packaging and technical documentation requests.

Compliance Statement

This product is supplied for laboratory research use only. It is not for human or animal administration, not for diagnostic or therapeutic use, not for retail sale, and not for personal use. Abaloparatide is approved as a prescription medicine (Tymlos) by the FDA (2017) for postmenopausal osteoporosis and for increasing bone density in men with osteoporosis; that regulatory status is specific to the approved pharmaceutical product and does not extend to this research-grade supply as sold by Knowlux. The EMA has previously issued a negative opinion for the EU marketing application (Eladynos) based on GCP compliance concerns regarding supporting studies. Abaloparatide carries a boxed warning regarding osteosarcoma risk in rats; this warning applies to the approved drug product and is noted here for reference only. Research context statements are for scientific reference only and do not constitute medical advice, promotional claims, or dosing guidance.